SCHEMBL11901522

SCHEMBL11901522

CC(C)(C)OC(=O)NC(c1ccccc1)c1nc2ccc(F)cc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 2/20 0.47
ALPL P05186 1/20 0.46
ALPI P09923 1/20 0.46
ALPG P10696 1/20 0.46
S1PR3 Q99500 2/20 0.44
BACE1 P56817 5/20 0.42
BACE2 Q9Y5Z0 4/20 0.42
PTPN1 P18031 1/20 0.42
GABRB1 P18505 1/20 0.41
GABRB2 P47870 1/20 0.41
MPO P05164 1/20 0.40
MLKL Q8NB16 1/20 0.40
PIN1 Q13526 1/20 0.40
KMT2A Q03164 2/20 0.40
S1PR1 P21453 1/20 0.40
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
PRMT5 O14744 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2504091 0.84 AAK1 (0.53) AAK1ALPLALPIALPGBACE1
SCHEMBL2504088 0.84 AAK1 (0.53) AAK1ALPLALPIALPGBACE1
SCHEMBL4792161 0.79 BCHE (0.47) AAK1PTPN1MLKLKMT2AMEN1
SCHEMBL14820895 0.74 CTSK (0.57) GABRB1GABRB2KMT2AMEN1LMNA
SCHEMBL2549911 0.73 AAK1 (0.54) AAK1
SCHEMBL8330091 0.72 TSHR (0.59) AAK1PTPN1KMT2ALMNAMAPT
SCHEMBL6304376 0.72 TSHR (0.59) AAK1PTPN1KMT2ALMNAMAPT
SCHEMBL1479477 0.71 AAK1 (0.44) AAK1S1PR3S1PR1
SCHEMBL19494664 0.71 CACNA1H (0.55) MPOPIN1LMNAGAABCHE
SCHEMBL2509706 0.71 ALPL (0.58) ALPLALPIALPGBACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 AAK1 1089/4885ALPL 1227/4885ALPI 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.